event < events < eventually

Facettes : Author.f AffPays.f AffRegion.f AffVille.f AffOrg.f Mesh.f MeshFr.f Teeft.f

List of bibliographic references

Number of relevant bibliographic references: 31.
[0-20] [0 - 20][0 - 31][20-30][20-40]

Ident.	Authors (with country if any)	Title
000014 (2020)	Puja Mehta ; Jessica J. Manson	What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis?
000035 (2020)	Limin Li [République populaire de Chine] ; Jie Liu [République populaire de Chine] ; Mengyuan Xu [République populaire de Chine] ; Hongjuan Yu [République populaire de Chine] ; Chengfang Lv [République populaire de Chine] ; Fenglin Cao [République populaire de Chine] ; Zhenkun Wang [République populaire de Chine] ; Yueyue Fu [République populaire de Chine] ; Mingwen Zhang [République populaire de Chine] ; Hongbin Meng [République populaire de Chine] ; Xiaoqian Zhang [République populaire de Chine] ; Liqing Kang [République populaire de Chine] ; Zhuo Zhang [République populaire de Chine] ; Jinmei Li [République populaire de Chine] ; Jiawei Feng [République populaire de Chine] ; Xin Lian [République populaire de Chine] ; Lei Yu [République populaire de Chine] ; Jin Zhou [République populaire de Chine]	Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients
000051 (2020)	Eun Hye Park [Corée du Sud] ; Eun Young Lee [Corée du Sud] ; Kichul Shin [Corée du Sud] ; Hyoun-Ah Kim [Corée du Sud]	Tocilizumab-induced anaphylaxis in patients with adult-onset Still's disease and systemic juvenile idiopathic arthritis: a case-based review.
000082 (2020)	Eun-Jung Park [Corée du Sud] ; Hyungjin Kim [Corée du Sud] ; Seung Min Jung [Corée du Sud] ; Yoon-Kyoung Sung [Corée du Sud] ; Han Joo Baek [Corée du Sud] ; Jisoo Lee [Corée du Sud]	The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus
000087 (2020)	Wanhai Ke ; Li Zhang ; Yan Dai	The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
000116 (2020)	Xi-Ying Wang [République populaire de Chine] ; Fen Zhang [République populaire de Chine] ; Chi Zhang [République populaire de Chine] ; Liang-Rong Zheng [République populaire de Chine] ; Jian Yang [République populaire de Chine]	The Biomarkers for Acute Myocardial Infarction and Heart Failure
000119 (2020)	Ana Paula Vargas Visentin [Brésil] ; Rafael Colombo [Brésil] ; Ellen Scotton [Brésil] ; Débora Soligo Fracasso [Brésil] ; Adriane Ribeiro Da Rosa [Brésil] ; Catia Santos Branco [Brésil] ; Mirian Salvador [Brésil]	Targeting Inflammatory-Mitochondrial Response in Major Depression: Current Evidence and Further Challenges
000141 (2020)	Adam Amlani [Canada] ; Claire Barber [Canada] ; Aurore Fifi-Mah [Canada] ; Jose Monzon [Canada]	Successful Treatment of Cytokine Release Syndrome with IL-6 Blockade in a Patient Transitioning from Immune-Checkpoint to MEK/BRAF Inhibition: A Case Report and Review of Literature.
000155 (2020)	Meng Xu ; Congcong Liu ; Lishuang Guo ; Sirui Yang	Severe sepsis caused by serious gastrointestinal infection in sJIA patients treated with IL-6 receptor antagonist: a case report
000169 (2020)	Maria Antonietta Barbieri [Italie] ; Giuseppe Cicala [Italie] ; Paola Maria Cutroneo [Italie] ; Elisabetta Gerratana [Italie] ; Caterina Palleria [Italie] ; Caterina De Sarro [Italie] ; Ada Vero [Italie] ; Luigi Iannone [Italie] ; Antonia Manti [Italie] ; Emilio Russo [Italie] ; Giovambattista De Sarro [Italie] ; Fabiola Atzeni [Italie] ; Edoardo Spina [Italie]	Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study.
000183 (2020)	Ibai Los-Arcos [Espagne] ; Juan Aguilar-Company [Espagne] ; Isabel Ruiz-Camps [Espagne]	Risk of infection associated with new therapies for lymphoproliferative syndromes.
000233 (2020)	Giulia Cassone [Italie] ; Marco Sebastiani [Italie] ; Caterina Vacchi [Italie] ; Stefania Cerri [Italie] ; Carlo Salvarani [Italie] ; Andreina Manfredi [Italie]	Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming?
000237 (2020)	Zaid H. Temrikar [États-Unis] ; Satyendra Suryawanshi [États-Unis] ; Bernd Meibohm [États-Unis]	Pharmacokinetics and Clinical Pharmacology of Monoclonal Antibodies in Pediatric Patients
000240 (2020)	James Kalmuk [États-Unis] ; Jon Puchalla [États-Unis] ; Gong Feng [États-Unis] ; Anshu Giri [États-Unis] ; John Kaczmar [États-Unis]	Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge
000265 (2020)	G. S. Braun [Allemagne] ; M. Kirschner [Allemagne] ; A. Rübben [Allemagne] ; R. U. Wahl [Allemagne] ; K. Amann [Allemagne] ; K. Benesova [Allemagne] ; J. Leipe [Allemagne]	Nebenwirkungen neuer onkologischer Immuntherapien
000288 (2020)	Xiaoyan Si ; Peng Song ; Jun Ni ; Mingyi Di ; Chunxia He ; Li Zhang ; Xiaowei Liu ; Yue Li ; Hanping Wang ; Xiaoxiao Guo ; Jiaxin Zhou ; Lian Duan ; Xu Yang ; Mengzhao Wang ; Li Zhang	Management of immune checkpoint inhibitor‐related adverse events: A review of case reports
000330 (2020)	Cécile Dumaine [France] ; Sara Bekkar [France] ; Alexandre Belot [France] ; Natalia Cabrera [France] ; Salma Malik [France] ; Annette Von Scheven [Suisse] ; Aurelia Carbasse [France] ; Andreas Woerner [Suisse] ; Carine Wouters [Belgique] ; Kenza Bouayed ; Pascal Pillet [France] ; Silke Schroeder [Suisse] ; Michael Hofer [Suisse] ; Véronique Hentgen [France]	Infectious adverse events in children with Juvenile Idiopathic Arthritis treated with Biological Agents in a real-life setting: Data from the JIRcohorte.
000344 (2020)	Sadaf Atiqi [Pays-Bas] ; Femke Hooijberg [Pays-Bas] ; Floris C. Loeff [Pays-Bas] ; Theo Rispens [Pays-Bas] ; Gerrit J. Wolbink [Pays-Bas]	Immunogenicity of TNF-Inhibitors
000345 (2020)		Immune-Related Adverse Events: Pneumonitis
000413 (2020)	Mauricio Cordero-Alfaro [Costa Rica] ; Carlos Le N-Céspedes [Costa Rica] ; Allan Ramos-Esquivel [Costa Rica]	Effectiveness of intravenous tocilizumab in routine clinical practice in a cohort of Costa Rican patients with rheumatoid arthritis.
000445 (2020)	A. Charlotte M. T. De Wolf ; Carla A. Herberts ; Marcel H. N. Hoefnagel	Dawn of Monitoring Regulatory T Cells in (Pre-)clinical Studies: Their Relevance Is Slowly Recognised

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/2020/Analysis

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i -k "events" 

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i  \
                -Sk "events" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    2020
   |étape=   Analysis
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    events
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021